Monitor ATLAS trial data readouts for efficacy signals; a positive Phase II/III result could significantly expand momelotinib's addressable market. Near-term stock impact likely muted as ODD is an early milestone with no revenue contribution.
Price Chart
Executive Summary
GSK announced that momelotinib received Orphan Drug Designation (ODD) from the FDA and EMA for VEXAS syndrome, a rare life-threatening condition with no approved treatments. The designation supports the ongoing phase II/III ATLAS trial and potential future regulatory submissions, expanding momelotinib's development program beyond myelofibrosis.
Key Facts
- Momelotinib granted Orphan Drug Designation (ODD) by FDA and EMA for VEXAS syndrome.
- VEXAS syndrome has a 30-40% five-year mortality rate and no approved treatments.
- Phase II/III ATLAS trial evaluating momelotinib in VEXAS is underway; study design presented at EHA Congress June 11-14, 2026.
- Momelotinib is already approved for myelofibrosis in the US, EU, UK, and Japan.
Financial Impact
No revenue impact yet; potential future revenue if approved for VEXAS, but current VEXAS market size is small and uncertain.
Risk Factors
- Clinical trial failure or underwhelming efficacy data could derail VEXAS indication.
- VEXAS syndrome is ultra-rare, limiting commercial upside even if approved.
- Competing therapies may emerge before ATLAS trial completes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005913 |
| Document: 0001654954-26-005913-index-headers.html | 0001654954-26-005913 |
| Document: 0001654954-26-005913-index.html | 0001654954-26-005913 |
| Document: 0001654954-26-005913.txt | 0001654954-26-005913 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access